BioCardia, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BioCardia announced it is working toward a Shonin pre-market submission to Japan's PMDA in Q4 2026 for CardiAMP autologous cell therapy, with potential market clearance by Q4 2027. The company also intends to submit a follow-on De Novo pre-submission for its Helix transendocardial delivery catheter to FDA CDRH this quarter, with FDA targeting initial review within 15 calendar days and feedback/meeting within 70 calendar days. CardiAMP HF II confirmatory trial is actively enrolling at four U.S. centers and FDA CBER has indicated the study may support a Premarket Application.
Why this rating
Major regulatory milestones for a $9.7M-cap biotech; dual-pathway approvals (Japan + US) could validate platform and unlock partnerships/commercialization, but remain contingent on trial success and regulatory acceptance.
Tradability signal
NO TRADE
No trade: positive news with only +1.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=113). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.05 ▲ 0.00% | at our read · unknown $1.05 | +10 min · unknown $1.05 ▲ 0.00% | +30 min · unknown $1.04 ▼ 0.95% | +1 hr pending | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.